Pasar al contenido principal

Conexión rápida

Noticias

Sugammadex Sodium API – CADIFA Approval by ANVISA

We are glad to announce the granting of the first CADIFA ever issued by ANVISA on the 08th of September 2021, regarding the API SUGAMMADEX SODIUM, under the requirements of the Resolution – RDC nº 359/2020. This is a landmark and a moment of great happiness for us that have worked relentlessly in partnership with ANVISA and our clients at the Pharmaceutical Industry to make this achievement come true.

Contact Us

Rellene el siguiente formulario y nos pondremos en contacto con usted a la brevedad.

Nuestra lienea de contacto email: api@drreddys.com | +91 40 49002253